Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
about
SLUG is required for SOX9 stabilization and functions to promote cancer stem cells and metastasis in human lung carcinomaThe role of the GP in follow-up cancer care: a systematic literature review.Associations of Radiomic Data Extracted from Static and Respiratory-Gated CT Scans with Disease Recurrence in Lung Cancer Patients Treated with SBRTQuantitative proteomics in lung cancer.Surgical strategies in the therapy of non-small cell lung cancer.Long noncoding RNAs expression patterns associated with chemo response to cisplatin based chemotherapy in lung squamous cell carcinoma patients.Lung Cancer Assistant: a hybrid clinical decision support application for lung cancer care.Predictive and prognostic biomarkers with therapeutic targets in breast, colorectal, and non-small cell lung cancers: a systemic review of current development, evidence, and recommendation.Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer. Mechanisms and therapeutic implications.Bayesian networks for clinical decision support in lung cancer care.TFIIB-related factor 2 over expression is a prognosis marker for early-stage non-small cell lung cancer correlated with tumor angiogenesis.SETDB1 accelerates tumourigenesis by regulating the WNT signalling pathway.A phase II study of cisplatin with intravenous and oral vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy with oral vinorelbine and cisplatin for locally advanced non-small cell lung cancer.How close are we to customizing chemotherapy in early non-small cell lung cancer?LAMC2 enhances the metastatic potential of lung adenocarcinoma.Genetic variation in the TNF/TRAF2/ASK1/p38 kinase signaling pathway as markers for postoperative pulmonary complications in lung cancer patients.The triptolide derivative MRx102 inhibits Wnt pathway activation and has potent anti-tumor effects in lung cancer.Evidence-practice gaps in lung cancer: A scoping review.Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancerThoracic Temporal Subtraction Three Dimensional Computed Tomography (3D-CT): Screening for Vertebral Metastases of Primary Lung Cancers.Risk factors for local and regional recurrence in patients with resected N0-N1 non-small-cell lung cancer, with implications for patient selection for adjuvant radiation therapy.MicroRNA-7 Compromises p53 Protein-dependent Apoptosis by Controlling the Expression of the Chromatin Remodeling Factor SMARCD1.A robust prognostic gene expression signature for early stage lung adenocarcinoma.Spectrum of EGFR gene mutations and ALK rearrangements in lung cancer patients in TurkeyConcurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: a randomised trial by the Norwegian Lung Cancer Study Group.The predictive value of 18F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapyThymidylate synthase inhibitors for non-small cell lung cancer.Integrated imaging of non-small cell lung cancer recurrence: CT and PET-CT findings, possible pitfalls and risk of recurrence criteria.Current clinical immunotherapy targets in advanced nonsmall cell lung cancer (NSCLC).Endobronchial ultrasound-guided transbronchial needle aspiration for non-small cell lung cancer staging.The Victorian Lung Cancer Registry pilot: improving the quality of lung cancer care through the use of a disease quality registry.MicroRNAs as ideal biomarkers for the diagnosis of lung cancer.Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?Commercially available prognostic molecular models in early-stage lung cancer: a review of the Pervenio Lung RS and Myriad myPlan Lung Cancer tests.Nintedanib in combination with docetaxel for second-line treatment of advanced non-small-cell lung cancer.Comparison of mediastinal lymph node status and relapse pattern in clinical stage IIIA non-small cell lung cancer patients treated with neoadjuvant chemotherapy versus upfront surgery: A single center experience.Nanoparticulation improves bioavailability of Erlotinib.Stephania Tetrandra and Ginseng-Containing Chinese Herbal Formulation NSENL Reverses Cisplatin Resistance in Lung Cancer Xenografts.Immune checkpoint therapy for non-small-cell lung cancer: an update.Overexpression of Sphk2 is associated with gefitinib resistance in non-small cell lung cancer.
P2860
Q23920671-6EEC13FD-D47C-4D82-AE51-24D92C3D14E8Q30241957-D3C9E312-F406-4463-87CD-395A1DBCC194Q31152462-09F60780-0079-4AE6-814C-2741831148E8Q33796358-6FFD963F-B37A-428A-B4FA-88B002490B13Q34031208-1195CC44-6669-4652-BD96-D40439EE9478Q34252809-05686B44-B5B1-4DC6-8E96-BDFEDD580CEAQ34521016-EE7110D8-7AF4-4D20-B6F7-6E4CA3F0C4E6Q34620545-798357E0-8140-48F4-AC1A-E2D2B4CA7494Q34987170-BCD161F1-A5E9-4BF3-973D-0C4F1CA2B306Q35064151-D92140D8-7AFA-4779-997F-2D18F918CF37Q35093552-7CA5BC2F-BBC1-44EC-8BA3-0C041BC27A1EQ35097426-5DF7E3FC-02F6-474A-BBFC-96A87ABEE24DQ35134354-CF0A7073-E9F4-4FAB-8FD0-26C1FB37A536Q35146944-8695C2F7-E1D4-4992-A01D-0BAB6F32077CQ35829871-992D6FDB-28EE-45B7-BB85-C39A93A48F57Q35844505-3748A296-3C70-4F20-97F5-D321A4C17098Q36072943-2A561F67-EFEE-482C-8873-79B3492530F2Q36162124-D1DEF798-3898-4B3F-8464-8DB9637EF3DBQ36201483-93F398C2-8FAC-4847-8BD0-228FB9A61AEEQ36251425-0DB05D58-663B-4796-9597-AAACBE7EE55CQ36474910-C488E803-CE42-4086-9C88-127A9D997BD9Q36489308-C9A96E3E-7C80-4B83-A597-8588F428751BQ36599994-3748C4BE-DBA4-48D0-831F-5D6F04962F18Q36815913-8B43B38C-4118-471C-83CB-55E1CE0D5E1AQ37182205-FE5E6251-C2B8-4E4A-9ED9-150D92999FEFQ37566016-30BDA5D5-2CC3-49C1-A57F-3967CAA41CCBQ37929783-87DD03BA-45A1-4D08-A179-D01C0D6AC955Q37942070-03246CB7-EE05-47D0-8603-D67374576A5AQ38108501-78068E95-35DA-4692-8ABE-96D1F19519E1Q38183919-A261B55E-C4CB-4422-9E7E-08F626C1B81BQ38218370-9F8F732A-627F-4B08-A36E-E0C26C9DBA71Q38232994-1321B09A-CD68-4F24-90A2-C1450CD78555Q38366141-ED0472BB-A607-4DD7-A579-9183976FEED0Q38432142-0D714847-9E78-404E-8A4A-D7EA5C47A221Q38552883-C4D02110-4389-43ED-BD80-BAFDF866CB1FQ38696794-F8E7B022-4402-4895-9005-B587BC3E56F9Q38701944-BE91AF19-5B4C-4CA1-9CE7-93B16D214405Q38715185-64A34C2C-8C3F-4F55-8507-67FD90745C88Q38727542-A8327719-7F4E-41EE-90F7-47164BCC5173Q38815102-52488AB3-BE89-483E-AD0E-8C598C71E163
P2860
Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
description
im Mai 2010 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 01 May 2010
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2010
@uk
name
Early stage and locally advanc ...... nosis, treatment and follow-up
@en
Early stage and locally advanc ...... nosis, treatment and follow-up
@nl
type
label
Early stage and locally advanc ...... nosis, treatment and follow-up
@en
Early stage and locally advanc ...... nosis, treatment and follow-up
@nl
prefLabel
Early stage and locally advanc ...... nosis, treatment and follow-up
@en
Early stage and locally advanc ...... nosis, treatment and follow-up
@nl
P2093
P2860
P356
P1433
P1476
Early stage and locally advanc ...... nosis, treatment and follow-up
@en
P2093
ESMO Guidelines Working Group
J van Meerbeeck
P2860
P304
P356
10.1093/ANNONC/MDQ207
P433
Supplement 5
P478
21 Suppl 5
P577
2010-05-01T00:00:00Z